CONFERENCE PROGRAM

Conference Cochairs

Douglas A. Levine, NYU Langone Health, New York, NY **Blake Gilks,** Vancouver Coastal Health Research Institute, Vancouver, BC, Canada **Victoria L. Bae-Jump,** University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

MONDAY, NOVEMBER 9, 2020

10:00 AM-11:30 AM	WELCOME AND EDUCATION SESSION Introduction by Douglas A. Levine, NYU Langone Health, New York, NY, C. Blake Gilks, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada, Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
10:00 AM-10:30 AM	Management of newly diagnosed endometrial cancers and molecular classification Douglas A. Levine
10:30 AM-11:00 AM	Histopathology classification of endometrial cancers and surrogate markers of genomic subtypes C. Blake Gilks
11:00 AM-11:30 AM	Navigating the complex world of adjuvant treatments and clinical trials Victoria L. Bae-Jump
11:30 AM-11:45 AM	BREAK
11:45 AM-1:30 PM	PLENARY SESSION 1: Targeted Therapeutics

^{*}Five minute (5 slide max) audio poster short talks in a single poster session will be released at the start of the conference and available on-demand throughout*

^{**}Presentations will be prerecorded. Presentation times are as follows: Keynote (30 minutes and 10 minutes for live Q&A); other invited presentations (20 minutes and 10 minutes for live Q&A), short talks selected from proffered abstracts, if applicable (10 minutes and 5 minutes for live Q&A)**

	Session Chair: Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
11:45 AM-12:15 PM	Challenges for future adjuvant studies and the role of immunotherapy in endometrial cancer Remi A. Nout, Leiden University Medical Center, Leiden, Netherlands
12:15 PM-12:45 PM	DNA damaging agents in endometrial cancer Shannon Neville Westin , The University of Texas MD Anderson Cancer Center, Houston, TX
12:45 PM-1:15 PM	Endocrine therapy and ER/PR combinations Helen J. MacKay, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
1:15 PM-1:30 PM	Preclinical development of SHetA2 for endometrial cancer therapy* Doris M. Benbrook, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
1:30 PM-1:45 PM	BREAK
1:45 PM-3:45 PM	PLENARY SESSION 2: Functional Genomics and Proteomics Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, NC
1:45 PM-3:45 PM 1:45 PM-2:15 PM	Session Chair: Russell R. Broaddus, University of North Carolina School of
	Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, NC The mutational landscape of normal human endometrial epithelium
1:45 PM-2:15 PM	Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, NC The mutational landscape of normal human endometrial epithelium Luiza Moore, Wellcome Trust Sanger Institute, Cambridge, England Mismatch repair deficiency and survival in stage I endometrial cancer
1:45 PM-2:15 PM 2:15 PM-2:45 PM	Session Chair: Russell R. Broaddus, University of North Carolina School of Medicine, Chapel Hill, NC The mutational landscape of normal human endometrial epithelium Luiza Moore, Wellcome Trust Sanger Institute, Cambridge, England Mismatch repair deficiency and survival in stage I endometrial cancer Russell R. Broaddus Proteogenomic characterization of endometrial carcinoma

3:45 PM-4:00 PM BREAK

4:00 PM-5:00 PM PLENARY SESSION 3: Immunotherapy

Session Chair: Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center,

New York, NY

4:00 PM-4:30 PM Immunology of endometrial cancers: Tumor genetics, immune

recognition, and immunotherapy response

Dmitriy Zamarin

4:30 PM-5:00 PM Coordinated T and B cell responses exert immune pressure against

malignant progression

Jose R. Conejo-Garcia, Moffitt Cancer Center, Tampa, FL

TUESDAY, NOVEMBER 10, 2020

10:00 AM-10:45 AM KEYNOTE LECTURE

Introduction by Douglas A. Levine, NYU Langone Health, New York, NY

Recent progress with PTEN

Ramon Parsons, Icahn School of Medicine at Mount Sinai, New York, NY

10:45 AM-11:00 AM BREAK

11:00 AM-12:30 PM PLENARY SESSION 4: DNA Repair and Replication

Session Chair: Tjalling Bosse, Leiden University Medical Center, Leiden,

Netherlands

11:00 AM-11:30 AM Endometrial carcinomas with a mutation in DNA polymerase epsilon:

A pathologist view

Tjalling Bosse

11:30 AM-12:00 PM	POLE mutations in endometrial cancer: Consequences and mechanisms Polina V. Shcherbakova, University of Nebraska Medical Center, Omaha, NE
12:00 PM-12:15 PM	Multi-dimensional biomarker analyses identify pembrolizumab responders in advanced stage, high grade endometrial cancer* Katherine C. Fuh, Washington University School of Medicine, St. Louis, MO
12:15 PM-12:30 PM	CD73 sequestering mutant β-catenin at the membrane explains recurrence in CTNNB1 mutant endometrial cancer* Jessica L. Bowser, University of North Carolina School of Medicine, Chapel Hill, NC
12:30 PM-12:45 PM	BREAK
12:45 PM-2:45 PM	PLENARY SESSION 5: Molecular Stratification Session Chair: Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada
12:45 PM-1:15 PM	Molecular stratification: Beyond TCGA David Church, Wellcome Centre for Human Genetics, University of Oxford, Oxford, England
1:15 PM-1:45 PM	Molecular stratification: p53abnormal endometrial carcinoma; the low-hanging fruit Naveena Singh, Barts Health NHS Trust, London, England
1:45 PM-2:15 PM	Molecular classification and stratification: Diving deeper Jessica N. McAlpine
2:15 PM-2:30 PM	Correlation of immunohistochemistry with <i>TP53</i> sequence and clinical outcomes in GOG-086P* Kimberly K. Leslie, University of Iowa, Iowa City, IA
2:30 PM-2:45 PM	Genomic characterisation of endometrial cancer patient-derived xenografts reveals intratumour heterogeneity* Olga Kondrashova, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
2:45 PM-3:00 PM	BREAK

3:00 PM-5:00 PM	PLENARY SESSION 6: Novel Model Systems Session Chair: Victoria L. Bae-Jump, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3:00 PM-3:30 PM	Breaking the obesity-endometrial cancer link: Lessons from preclinical studies Stephen D. Hursting, University of North Carolina Chapel Hill, Chapel Hill, NC
3:30 PM-4:00 PM	Organoids to model endometrial carcinoma subtypes David G. Huntsman, British Columbia Cancer Research Center, Vancouver, BC, Canada
4:00 PM-4:30 PM	Chromatin regulation of the endometrium: What are our models telling us? Ronald L. Chandler, Michigan State University, Grand Rapids, MI
4:30 PM-4:45 PM	Identifying mechanisms of immune evasion in microsatellite instable endometrial cancer mouse models* Brenda Melendez, The University of Texas MD Anderson Cancer Center, Houston, TX
4:45 PM-5:00 PM	Characterization of patient-derived xenograft models of endometrial cancer* Kristina W. Thiel, University of Iowa, Iowa City, IA

^{*}Short talk from proffered abstract